Hepatitis C in renal transplant recipients

Area of Science:

• Nephrology
• Hepatology
• Infectious Diseases

Background:

• Renal transplant recipients are a vulnerable population for infections.
• Hepatitis C virus (HCV) poses a significant health risk, especially in immunocompromised individuals.
• Understanding HCV prevalence and transmission routes in this cohort is crucial for patient management.

Purpose of the Study:

• To determine the prevalence of antibody to hepatitis C virus (anti-HCV) in renal transplant recipients.
• To investigate potential sources of HCV infection, such as dialysis methods and transfusions.
• To explore the relationship between anti-HCV status and liver enzyme elevations.

Main Methods:

• Sera from 130 renal transplant recipients were tested for anti-HCV.
• Prevalence rates were compared between patients who underwent maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) prior to transplantation.
• Association with elevated serum transaminase levels and hepatitis B surface antigen (HBsAg) status was examined.

Main Results:

• Anti-HCV was detected in 6.2% of renal transplant recipients.
• Patients on maintenance HD showed a significantly higher prevalence (15.4%) compared to CAPD patients (2.2%).
• Elevated transaminases were common in anti-HCV positive patients (75%), similar to HBsAg-positive patients (72.2%), but less common in HBsAg-negative patients with elevated transaminases (25%).

Conclusions:

• HCV infection is a concern in renal transplant recipients, with hemodialysis identified as a likely source of transmission.
• The findings suggest that most HCV infections were acquired during dialysis prior to transplantation.
• Further research is needed to clarify the role of other hepatitis viruses or immunosuppression in anti-HCV detection post-transplantation.